Cardiac care is suffering at hospitals that experience data breaches, PBS reported Oct. 24, with one study finding that heart attack rates soar in the weeks and months after a center’s cybersecurity is compromised.
Cardiology is in the midst of a major transition from one of its best-loved tools—the stethoscope—to more high-tech handheld solutions, according to the AP. But does that mean the original device is becoming obsolete?
The largest study of its kind has found that taking blood pressure medication at bedtime—as opposed to first thing in the morning—lowers heart patients’ risk of death and CV-related illness in the long run.
A novel machine learning algorithm improved patient selection for CRT in a study of nearly 1,000 heart failure patients, representing an opportunity to optimize care and spare certain individuals from a pricey procedure that might not benefit them.
Pharmaceutical company AstraZeneca announced Oct. 21 that its drug Farxiga—or dapagliflozin—was approved by the FDA to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.